Abstract: The present invention provides polymer blends that can be used in a multilayer structure and to multilayer structures comprising one or more layers formed from such blends. In one aspect, a polymer blend comprises (a) a copolymer comprising ethylene and at least one of acrylic acid and methacrylic acid having an acid content of 2 to 21 weight percent based on the weight of the copolymer, wherein the amount of copolymer (a) comprises 20-80 weight percent of the blend based on the total weight of the blend, and (b) a copolymer comprising ethylene and at least one of methyl acrylate and ethyl acrylate having an acrylate content of 5 to 30 weight percent based on the weight of the copolymer, wherein the amount of copolymer (b) comprises 10 to 50 weight percent of the blend based on the total weight of the blend, wherein the amount of copolymer (a) and copolymer (b) is at least 70 weight percent of the blend based on the total weight of the blend.

Abstract: A process to form a polymer composition comprising an ethylene-based polymer and a functionalized ethylene-based polymer, said process comprising the steps described herein, which include passing a polymer melt through at least one static mixer, and wherein the functionalized ethylene-based polymer, in melt form, is introduced into the polymer melt, before the polymer melt enters the static mixer.

Abstract: The present invention provides multilayer structures and articles formed from such structures. In one aspect, a multilayer structure comprises (a) a biaxially oriented polyethylene film comprising an outer layer that comprises a first polyethylene composition comprising at least two linear low density polyethylenes, wherein the first polyethylene composition has a density of 0.910 to 0.940 g/cm3, an MWHDE>95 greater than 135 kg/mol and an IHDE>95 greater than 42 kg/mol, wherein the film has a thickness of 10 to 60 microns after orientation; and (b) a metal layer comprising a metal deposited on the outer layer, wherein the metal comprises Al, Zn, Au, Ag, Cu, Ni, Cr, Ge, Se, Ti, Sn, or oxides thereof, and wherein the multilayer structure has an optical density of 1.0 to 3.

Abstract: Disclosed herein is a multilayered film comprising a first layer and a second layer; and a tie layer; where the tie layer comprises a crystalline block composite and where the tie layer is disposed between the first layer and the second layer; the first layer being disposed on a first surface of the tie layer; the second layer being disposed on a second surface of the tie layer; where the second surface is opposedly disposed to the first surface; where the multilayered film is biaxially oriented. Disclosed herein too is a method of manufacturing the aforementioned multilayer film.

Abstract: A first oriented film comprising a first polyethylene composition which comprises: from 20 to 50 wt % of a first linear low density polyethylene polymer having a density greater than 0.925 g/cc and an I2 lower than 2 g/10 min; and from 80 to 50 wt % of a second linear low density polyethylene polymer having a density lower than or equal to 0.925 g/cc and an I2 greater than or equal to 2 g/10 min; wherein the first polyethylene composition has an 12 from 0.5 to 10 g/10 min and a density from 0.910 to 0.940 g/cc is provided.

Abstract: A first oriented film comprising a first polyethylene composition which comprises: from 20 to 50 wt % of a first linear low density polyethylene polymer having a density greater than 0.925 g/cc and an I2 lower than 2 g/10 min; and from 80 to 50 wt % of a second linear low density polyethylene polymer having a density lower than or equal to 0.925 g/cc and an I2 greater than or equal to 2 g/10 min; wherein the first polyethylene composition has an I2 from 0.5 to 10 g/10 min and a density from 0.910 to 0.940 g/cc is provided.

Abstract: The present invention discloses a process for forming a biaxially oriented film. The process includes first selecting a polyolefin resin wherein said polyolefin resin comprises a linear low density polyethylene resin characterized by having from 9 to 35 weight percent of the total weight of linear low density polyethylene resin eluting from a CEF at a temperature greater than 97.0° C.; and further characterized by having a CDR of from 33 to 80 and a Mw Ratio of from 0.15 to 0.45. Next a film is formed from the polyolefin resin selected in the first step. Finally the film formed in the second step is oriented in a sequential manner. The films produced by this process are characterized by having an ultimate elongation at least 1.5 times greater in the MD as compared to the CD and the 2% secant modulus is a least 1.25 times greater in the CD as compared to the MD.

Abstract: Embodiments of the present invention relate to biaxially oriented, multilayer polyethylene films and to laminates and articles formed therefrom. In one aspect, a biaxially oriented, multilayer polyethylene film comprises Layer A which is a sealant layer p having a top facial surface and a bottom facial surface and comprising a first polyethylene, wherein the first polyethylene has a density of at least 0.900 g/cm3, an IHDF>95 of 20-60 kg/mol, and a MWHDF>95 of greater than 130 kg/mol, wherein Layer A comprises at least 50 weight percent of the first polyethylene based on the weight of Layer A, and Layer B having a top facial surface and a bottom facial surface, wherein Layer B comprises one or more additional polyethylenes, and wherein the top facial surface of Layer B is in adhering contact with a bottom facial surface of Layer A, wherein the density of the first polyethylene is at least 0.002 g/cm3 less than the density of Layer B.

Abstract: Embodiments of the present invention relate to multilayer structures and articles formed therefrom. In one aspect, a multilayer structure comprises (a) a biaxially oriented polyethylene film comprising a linear low density polyethylene having a density of 0.910 to 0.

Abstract: The present invention relates to compounds of formula I that are metallo-?-lactamase inhibitors, the synthesis of such compounds, and the use of such compounds for use with ?-lactam antibiotics for overcoming resistance.

Abstract: A multilayer structure comprising at least one skin sealant layer, wherein the skin layer comprises a polyethylene having a crystallinity, CS; a tie layer which comprises a first polyethylene having a crystallinity, CT, wherein the tie layer is adhered to the skin layer; and a bulk layer which comprises a second polyethylene having a crystallinity, CB, wherein the tie layer is disposed between the bulk layer and the skin sealant layer; wherein CB>CT>CS; and wherein the layers are coextruded and the multilayer structure oriented by a semi-molten orientation process is provided. Also provided is a laminate comprising the multilayer structure and articles comprising the laminate.

Abstract: A boss configured to mount a nitrous oxide sensor in an exhaust conduit is disclosed. The boss includes a first tier configured to contact with an exterior surface of the exhaust conduit, the first tier defined by a first diameter and a first height. The boss also includes a second tier extending from the first tier. The second tier is configured to be disposed within an interior space defined within the exhaust conduit. The second tier is defined by a second diameter and a second height. Further, the second diameter is sized smaller than the first diameter. The boss further includes a condensation protection feature configured to direct condensation away from the nitrous oxide sensor.

Abstract: The present invention relates to compounds of formula I that are metallo-?-lactamase inhibitors, the synthesis of such compounds, and the use of such compounds for use with ?-lactam antibiotics for overcoming resistance.

Abstract: A first oriented film comprising a first polyethylene composition which comprises: from 20 to 50 wt % of a first linear low density polyethylene polymer having a density greater than 0.925 g/cc and an I2 lower than 2 g/10 min; and from 80 to 50 wt % of a second linear low density polyethylene polymer having a density lower than or equal to 0.925 g/cc and an I2 greater than or equal to 2 g/10 min; wherein the first polyethylene composition has an 12 from 0.5 to 10 g/10 min and a density from 0.910 to 0.940 g/cc is provided.

Abstract: Disclosed herein is a multilayered film comprising a first layer and a second layer; and a tie layer; where the tie layer comprises a crystalline block composite and where the tie layer is disposed between the first layer and the second layer; the first layer being disposed on a first surface of the tie layer; the second layer being disposed on a second surface of the tie layer; where the second surface is opposedly disposed to the first surface; where the multilayered film is biaxially oriented. Disclosed herein too is a method of manufacturing the aforementioned multilayer film.

Abstract: A boss configured to mount a nitrous oxide sensor in an exhaust conduit is disclosed. The boss includes a first tier configured to contact with an exterior surface of the exhaust conduit, the first tier defined by a first diameter and a first height. The boss also includes a second tier extending from the first tier. The second tier is configured to be disposed within an interior space defined within the exhaust conduit. The second tier is defined by a second diameter and a second height. Further, the second diameter is sized smaller than the first diameter. The boss further includes a condensation protection feature configured to direct condensation away from the nitrous oxide sensor.

Abstract: Disclosed are compounds of the formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein each variable in Formula 1 are as defined in the specification; and pharmaceutical compositions comprising the compounds of formula I. Also disclosed are methods of inhibiting aspartyl protease, and in particular, the methods of treating cardiovascular diseases, cognitive and neurodegenerative diseases, and the methods of inhibiting of Human Immunodeficiency Virus, plasmepins, cathepsin D and protozoal enzymes. Also disclosed are methods of treating cognitive or neurodegenerative diseases using the compounds of formula I in combination with a cholinesterase inhibitor or a muscarinic m1 agonist or m2 antagonist.

Abstract: Disclosed are compounds of the formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein each variable in Formula 1 are as defined in the specification; and pharmaceutical compositions comprising the compounds of formula I. Also disclosed are methods of inhibiting aspartyl protease, and in particular, the methods of treating cardiovascular diseases, cognitive and neurodegenerative diseases, and the methods of inhibiting of Human Immunodeficiency Virus, plasmepins, cathepsin D and protozoal enzymes. Also disclosed are methods of treating cognitive or neurodegenerative diseases using the compounds of formula I in combination with a cholinesterase inhibitor or a muscarinic m1 agonist or m2 antagonist.

Abstract: Disclosed are compounds of the formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein each variable in Formula I are as defined in the specification; and pharmaceutical compositions comprising the compounds of formula I. Also disclosed are methods of inhibiting aspartyl protease, and in particular, the methods of treating cardiovascular diseases, cognitive and neurodegenerative diseases, and the methods of inhibiting of Human Immunodeficiency Virus, plasmepins, cathepsin D and protozoal enzymes. Also disclosed are methods of treating cognitive or neurodegenerative diseases using the compounds of formula I in combination with a cholinesterase inhibitor or a muscarinic m1 agonist or m2 antagonist.

Abstract: Disclosed are compounds of the formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein each variable in Formula 1 are as defined in the specification; and pharmaceutical compositions comprising the compounds of formula I. Also disclosed are methods of inhibiting aspartyl protease, and in particular, the methods of treating cardiovascular diseases, cognitive and neurodegenerative diseases, and the methods of inhibiting of Human Immunodeficiency Virus, plasmepins, cathepsin D and protozoal enzymes. Also disclosed are methods of treating cognitive or neurodegenerative diseases using the compounds of formula I in combination with a cholinesterase inhibitor or a muscarinic m1 agonist or m2 antagonist.